Helping employees with cancer return to work by supporting their employers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized controlled trial evaluates the MiLES intervention, which provides employers with resources and support to facilitate the successful return to work (RTW) of employees diagnosed with cancer. The study includes 140 employer-employee dyads, with participants randomly assigned to either receive the MiLES intervention or standard care. The primary outcome is the successful RTW of employees, while secondary outcomes assess quality of life, work-related support, and employer satisfaction. Data will be collected through questionnaires at multiple follow-up points over a year.

Why it matters

Who can join: the full rules

Inclusion criteria employees with cancer:

* Diagnosed with cancer \<2 years earlier;
* Being of working age (between 18-65 years, considering the Dutch retirement age of 67 years, and the study's follow-up period of one year);
* In paid employment with an employer;
* Having either an occupational physician at the involved occupational health service or a reintegration consultant at the involved reintegration service (e.g. working for an organization that is affiliated with one of the settings of this study);
* Currently fully or partly sick-listed (\<2 years);
* Able to understand and read Dutch for filling out questionnaires;
* Having already informed their employer about their diagnosis of cancer, or intending to do so;
* Not yet applied or planning to apply for an invalidity benefit under the WIA.

Inclusion criteria employers:

* Supports and guides the participating employee with cancer during the period of sick leave and RTW. For example, as the direct supervisor or HR-manager;
* Able to understand and read Dutch to be able to use the MiLES intervention and for filling out questionnaires;
* Not yet familiar with the MiLES intervention.

Exclusion Criteria:

\- Employees with cancer and their employers must participate as a dyad. If one party in the dyad is unable or unwilling to participate, the other party cannot participate either.

Where it's running

• Arbo Unie
  Arnhem, Netherlands Recruiting
• Arbo Unie
  Dordrecht, Netherlands Recruiting
• Arbo Unie
  Hengelo, Netherlands Recruiting
• Re-turn
  Utrecht, Netherlands Recruiting
• Arbo Unie
  Zeeland, Netherlands Recruiting

Study contacts

• Principal investigator: Sietske Tamminga, PhD — Amsterdam UMC, location AMC
• Study coordinator: Judith Mollet, MSc
• Email: milesonderzoek@amsterdamumc.nl
• Phone: +31205669111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 4D MRI parameters linked to cardiovascular and cancer disease outcomes

  This study tests whether 4D MRI measurements can predict how cardiovascular diseases and cancer will progress in adults undergoing routine cardiac MRI at a single Korean hospital.

  Recruiting Ulsan University Hospital · Ulsan, Ulsan · NCT07678606

• Intratumoral injection of mechanically reprogrammed macrophage-derived exosomes for advanced solid tumors

  This trial will test whether injecting mechanically reprogrammed macrophage-derived exosomes directly into tumors is safe and tolerable in adults 18–65 with advanced solid tumors who have no standard treatment options.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07563972

• EMDR group program with optional individual EMDR for people with cancer

  This project will try EMDR group therapy plus optional individual EMDR to reduce PTSD symptoms and psychological distress in people diagnosed with cancer.

  Recruiting Università Cattolica di Milano · Milan · NCT07447089

• KLN-1010 gene therapy for relapsed or refractory multiple myeloma

  This Phase 1 trial will try KLN-1010, an in vivo CAR‑T gene therapy, to see if it is safe and can be given at a tolerable dose for people with relapsed or refractory multiple myeloma who have had at least three prior therapies.

  Recruiting at 11 sites Phase 1 Kelonia Therapeutics, Inc. · Duarte, California and 10 other locations · NCT07075185

• Creating a network for precision oncology in central-southern Italy

  This study is trying to create a network of labs in central-southern Italy to better understand cancer by improving testing methods and sharing information about tumors to help personalize treatment for patients.

  Recruiting National Cancer Institute, Naples · Naples · NCT06894823

• Adaptive care for Chinese cancer survivors with insomnia

  This study is testing whether a web-based therapy for insomnia or an online exercise program can help Chinese cancer survivors sleep better, and if those who still have trouble can benefit from more intensive face-to-face support.

  Recruiting The University of Hong Kong · Hong Kong · NCT06813235

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.